Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11C]DASB Positron Emission Tomography Study
Tóm tắt
Từ khóa
Tài liệu tham khảo
Pirker W, Asenbaum S, Kasper S, Walter H, Angelberger P, Koch G, Pozzera A, Deecke L, Podreka I, Brucke T: β-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect 1995; 100:247–256
Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S: Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [11C]DASB PET imaging study. Am J Psychiatry 2001; 158:1843–1849
Quitkin FM, Rabkin JG, Gerald J, Davis JM, Klein DF: Validity of clinical trials of antidepressants. Am J Psychiatry 2000; 157:327–337
Thase ME, Entsuah AR, Rudolph RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178:234–241
Owens MJ, Morgan WN, Plott SJ, Nemeroff CB: Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997; 283:1305–1322
Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340:249–258
Kapur SJ, Zipursky R, Jones C, Remington G, Houle S: Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157:514–520
Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G: Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538–544
Wilson AA, Ginovart N, Schmidt M, Meyer JH, Threlkeld PG, Houle S: Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines. J Med Chem 2000; 43:3103–3110
Wilson AA, Ginovart N, Hussey D, Meyer J, Houle S: In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol 2002; 29:509–515
Houle S, Ginovart N, Hussey D, Meyer JH, Wilson AA: Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB. Eur J Nucl Med 2000; 27:1719–1722
Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S: Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab 2001; 21:1342–1353
Szabo Z, Kao P, Scheffel U, Suehiro M, Mathews W, Ravert H, Musachio J, Marenco S, Kim S, Ricaurte G, Wong D, Wagner H, Dannals R: Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652. Synapse 1995; 20:37–43
Ikoma Y, Suhara T, Toyama H, Ichimiya T, Takano A, Sudo Y, Inoue M, Suzuki K: Quantitative analysis for estimating binding potential of brain serotonin transporters with [11C]McN5652. J Cereb Blood Flow Metab 2002; 22:490–501
Parsey RV, Kegeles LS, Hwang DR, Simpson N, Abi-Dargham A, Mawlawi O, Slifstein M, Van Heertum RL, Mann JJ, Laruelle M: In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. J Nucl Med 2000; 41:1465–1477
Laruelle M, Giddings SS, Zea-Ponce Y, Charney DS, Neumeyer JL, Baldwin RM, Innis RB: Methyl 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylate in vitro binding to dopamine and serotonin transporters under “physiological” conditions. J Neurochem 1994; 62:978–986
Carroll FI, Kotian P, Dehghani A, Gray JL, Kuzemko MA, Parham KA, Abraham P, Lewin AH, Boja JW, Kuhar MJ: Cocaine and 3 beta-(4′-substituted phenyl)tropane-2 beta-carboxylic acid ester and amide analogues: new high-affinity and selective compounds for the dopamine transporter. J Med Chem 1995; 38:379–388
Tauscher J, Pirker W, de Zwaan M, Asenbaum S, Brucke T, Kasper S: In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. Eur Neuropsychopharmacol 1999; 9:177–179
Lesch KP, Heils A, Riederer P: The role of neurotransporters in excitotoxicity, neuronal cell death, and other neurodegenerative processes. J Mol Med 1996; 74:365–378
Spencer E: An improved method for the measurement of paroxetine in human/serum plasma by HPLC with fluorescence detection (abstract). Ther Drug Monit 1999; 21:483
Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL: Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16:834–840
Burger C, Buck A: Requirements and implementation of a flexible kinetic modelling tool. J Nucl Med 1997; 38:1818–1823
Cortes R, Soriano E, Pazos A, Probst A, Palacios JM: Autoradiography of antidepressant binding sites in the human brain: localization using [3H]imipramine and [3H]paroxetine. Neuroscience 1988; 27:473–496
Backstrom I, Bergstrom M, Marcusson J: High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue. Brain Res 1989; 486:261–268
Laruelle M, Vanisberg M-A, Maloteaux J-M: Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites. Biol Psychiatry 1988; 24:299–309
Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ: A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984; 15:217–227
Meyer JH, Ichise M: Modeling of receptor ligand data in PET and SPECT imaging: a review of major approaches. J Neuroimaging 2001; 11:30–39
Studholme C, Hill D, Hawkes D: An overlap invariant entropy measure of 3D medical image alignment. Pattern Recognition 1999; 32:71–86
Meyer JH, Kapur S, Houle S, DaSilva J, Owczarek B, Brown GM, Wilson AA, Kennedy SH: Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study. Am J Psychiatry 1999; 156:1029–1034
Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, DaSilva JN, Wilson AA, Blak T, Eynan-Harvey R, Goulding VS, Houle S, Links P: Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry 2003; 160:90–99
Feighner JP, Overo K: Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry 1999; 60:824–830
Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M: Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 1988; 24:183–188
Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM, Dube S, Small JG: Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995; 38:592–602
Ballus C, Quiros G, De Flores T, de la Torre J, Palao D, Rojo L, Gutierrez M, Casais L, Riesgo Y: The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol 2000; 15:43–48
Zhou FC, Tao-Cheng JH, Segu L, Patel T, Wang Y: Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence. Brain Res 1998; 805:241–254
Bel N, Artigas F: Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 1992; 229:101–103
Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, Wilson AA, Rafi-Tari S, Mayberg HS, Kennedy SH: The effect of paroxetine on 5-HT2A receptors in depression: an [18F]setoperone PET imaging study. Am J Psychiatry 2001; 158:78–85
Blier P, Chaput Y, de Montigny C: Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: an electrophysiological study in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1988; 337:246–254
Duman R, Heninger G, Nestler E: A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54:597–606
Dowlatshahi D, MacQueen G, Wang J, Young L: Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet 1998; 352:1754–1755
Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S: [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. Synapse 2003; 47:123–133